Navigation Links
Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
Date:5/30/2013

DALLAS, May 30, 2013 /PRNewswire/ -- Securities lawyers at Deans & Lyons announced an investigation of the board of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) for a proposed sale to AstraZeneca. OMTH investors are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.

Although at least one analyst estimated the value could reach $15 per share before the deal was announced, OMTH stockholders will receive only $12.70 per share upon the acquisition by AstraZeneca. The investigation seeks to ensure OMTH stockholders obtain the highest price reasonably available in this buyout in addition to the disclosure of all important information.

The securities lawyers of Deans & Lyons have significant experience representing investors nationwide in representative actions involving securities at no cost to its clients.  Stockholders with concerns about this OMTH stock or anyone with information about this transaction should contact Hamilton Lindley at hlindley@deanslyons.com or 877-819-8033.

Hamilton Lindley
Deans & Lyons LLP
325 N. Saint Paul Street , Suite 1500
Dallas, TX 75201
(877) 819-8033 Toll Free
(214) 965-8500 Telephone
(214) 965-8505 Facsimile
hlindley@deanslyons.com
deanslyons.com


'/>"/>
SOURCE Deans & Lyons LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
2. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
3. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
5. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
6. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
9. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
10. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
11. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
Breaking Medicine Technology:
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... Thailand (PRWEB) , ... August 19, 2017 , ... ... Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness ... in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business ...
Breaking Medicine News(10 mins):